Yu Shan Song

Part of Sichuan Jinxin Reproductive Medical Investment Management Co, Shenzhen Zhongshan Urological Hospital is a hospital specializing in urological treatments. The hospital is based in Shenzhen, China. The hospital has a strong focus on research, with 42 research projects and 264 clinical trials currently ongoing. The Chinese company was founded in 1986 and has since expanded to include 351 beds, with 71 of them being in intensive care. The CEO is Jiang Lin Deng.

Part of Sichuan Jinxin Reproductive Medical Investment Management Co, Shenzhen Zhongshan Urological Hospital is a hospital specializing in urological treatments. The hospital is based in Shenzhen, China. The hospital has a strong focus on research, with 42 research projects and 264 clinical trials currently ongoing. The Chinese company was founded in 1986 and has since expanded to include 351 beds, with 71 of them being in intensive care. The CEO is Jiang Lin Deng.

Part of Sichuan Jinxin Reproductive Medical Investment Management Co, Shenzhen Zhongshan Urological Hospital is a hospital specializing in urological treatments. The hospital is based in Shenzhen, China. The hospital has a strong focus on research, with 42 research projects and 264 clinical trials currently ongoing. The Chinese company was founded in 1986 and has since expanded to include 351 beds, with 71 of them being in intensive care. The CEO is Jiang Lin Deng.

Part of Sichuan Jinxin Reproductive Medical Investment Management Co, Shenzhen Zhongshan Urological Hospital is a hospital specializing in urological treatments. The hospital is based in Shenzhen, China. The hospital has a strong focus on research, with 42 research projects and 264 clinical trials currently ongoing. The Chinese company was founded in 1986 and has since expanded to include 351 beds, with 71 of them being in intensive care. The CEO is Jiang Lin Deng.

Part of Sichuan Jinxin Reproductive Medical Investment Management Co, Shenzhen Zhongshan Urological Hospital is a hospital specializing in urological treatments. The hospital is based in Shenzhen, China. The hospital has a strong focus on research, with 42 research projects and 264 clinical trials currently ongoing. The Chinese company was founded in 1986 and has since expanded to include 351 beds, with 71 of them being in intensive care. The CEO is Jiang Lin Deng.